Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis

Ankylosing Spondylitis Clinical Trial

Official title:

Observational Study Of The Use Of Enbrel (Registered) (Etanercept) In Routine Clinical Practice To Treat Ankylosing Spondylitis (as) Patients: An Effectiveness, Safety, And Health Economic Evaluation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00544557
• Other study ID #: 0881X1-4463
• Secondary ID: B1801087
• Status: Completed
• Phase: Phase 4
• First received: October 15, 2007
• Last updated: April 23, 2015
• Start date: October 2007
• Est. completion date: May 2014

Study information

• Verified date: April 2015
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Ethics Commission
• Study type: Observational

Clinical Trial Summary

This study aims to provide a holistic assessment of patients receiving etanercept in a real-world setting.

Description:

Non-interventional study: subjects to be selected according to the usual clinical practice of their physician

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1715
• Est. completion date: May 2014
• Est. primary completion date: May 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of ankylosing spondylitis (AS)

Exclusion Criteria:

• Hypersensitivity to etanercept

• Active infection including chronic or localised infection

• Sepsis or risk of sepsis

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Ankylosing Spondylitis
• Spondylitis
• Spondylitis, Ankylosing

Intervention

Drug:
• Etanercept
The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.

Locations

Country	Name	City	State
Germany	Klinikum Benjamin Franklin	Berlin

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants Achieving Partial Remission at Week 26	Percentage of participants achieving partial remission was determined by assessment of spondyloarthritis international society (ASAS) criteria. Partial remission was defined as a score of less than 2 units (on a scale of 0-10, where 0= no disease activity and 10= high disease activity) in each of the 4 assessment in ASAS domains: participant global assessment of disease activity, pain, function, and inflammation.	Week 26	No
Primary	Percentage of Participants Achieving Partial Remission at Week 52	Percentage of participants achieving partial remission was determined by ASAS criteria. Partial remission defined as a score of less than 2 units (on a scale of 0-10, where 0= no disease activity and 10= high disease activity) in each of the 4 assessment in ASAS domains: participant global assessment of disease activity, pain, function, and inflammation.	Week 52	No
Secondary	Percentage of Participants With Serious Adverse Events (SAEs) or Adverse Events (AEs)	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life- threatening experience (immediate risk of dying); persistent or significant disability or incapacity; congenital anomaly. Percentage of participants with AEs included participants affected with both SAEs and non--SAEs.	Baseline up to Week 52	Yes
Secondary	Percentage of Participants With Serious Adverse Events (SAEs) or Adverse Events (AEs) by Co-morbidity		Baseline up to Week 52	Yes
Secondary	Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 52	BASDAI is a validated self-assessment tool used to determine disease activity in participant with AS. Utilizing a 11-point Likert-scale (0= none and 10=very severe) participant's answered 6 questions measuring discomfort, pain and fatigue. The index was computed by adding questions 1 to 4 plus the mean of questions 5 and 6. The resulting 0 to 50 score was divided by 5 to give a final 0-10 BASDAI score (0 being no problem and 10 being the worst problem).	Baseline, Week 52	No
Secondary	Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 52	BASFI is a validated self assessment tool that determines the degree of functional limitation in AS. Participants answered 10 questions, consisting of 8 specific questions regarding function in AS and 2 questions reflecting the participant's ability to cope with everyday life. Each question was answered on a 0-10 scale (0 being no problem and 10 being the worst problem), the sum of which (divided by 10) resulted in the BASFI score (0-10).	Baseline, Week 52	No
Secondary	Change From Baseline in Occiput-to-Wall Distance at Week 52	Occiput-to-wall distance is the distance between the occiput (posterior or back portion of the head) and the wall when the participant stood with heels and shoulder against the wall and the back straight.	Baseline, Week 52	No
Secondary	Change From Baseline in Lateral Lumbar Flexion at Week 52	Lateral lumbar flexion was determined by the difference of the finger-floor-distance in normal position and in lateral bending position.	Baseline, Week 52	No
Secondary	Change From Baseline in Patient's Global Assessment (PtGA) of Pain at Week 52	Participants were asked to assess their global pain intensity within the past 7 days. Pain was evaluated on an 11-point Likert scale: min = 0 (best), max = 10 (worst).	Baseline, Week 52	No
Secondary	Change From Baseline in Patient Global Assessment (PtGA) of Disease Activity at Week 52	Participants were asked to assess their disease activity within the past 7 days. Disease activity was evaluated on an 11-point Likert scale: min = 0 (best), max = 10 (worst).	Baseline, Week 52	No
Secondary	Change From Baseline in Physician Global Assessment (PGA) of Disease Activity at Week 52	Physicians were asked to assess the disease activity of participants within the past 7 days. Disease activity was evaluated on an 11-point Likert scale: min = 0 (best), max = 10 (worst).	Baseline, Week 52	No
Secondary	Change From Baseline in Duration of Morning Stiffness at Week 52	Duration of morning stiffness is defined as the time elapsed when participant woke up in the morning and was able to resume normal activities without stiffness in minutes.	Baseline, Week 52	No
Secondary	Percentage of Participants With Significant Reduction of Morning Stiffness	Duration of morning stiffness is defined as the time elapsed when participant woke up in the morning and was able to resume normal activities without stiffness in minutes. A significant reduction of duration of morning stiffness is defined as a reduction of the duration in minutes by at least 20 percent or reduction to 'no morning stiffness' (absence of morning stiffness).	Week 2, 6, 12, 26, 38, 52	No
Secondary	Percentage of Participants With Presence of Peripheral Arthritis	Peripheral arthritis is the inflammation of joints that involved asymmetrically. It involved the hips, shoulder girdle (glenohumeral, acromioclavicular, and sternoclavicular joints), joints of the chest wall (costovertebral joints, costosternal junctions) and symphysis pubis.	Baseline, Week 2, 6, 12, 26, 38, 52	No
Secondary	Change From Baseline in Number of Affected Joints by Peripheral Arthritis at Week 52	Peripheral arthritis is the inflammation of joints that involved asymmetrically. It involved the hips, shoulder girdle (glenohumeral, acromioclavicular, and sternoclavicular joints), joints of the chest wall (costovertebral joints, costosternal junctions) and symphysis pubis. In case of no presence of peripheral arthritis the number of affected joints was set to 0.	Baseline, Week 52	No
Secondary	Percentage of Participants With Presence of Enthesitis	Enthesitis is the inflammation of the enthesis, where the joint capsules, ligaments or tendons attach to the bone. This inflammation can lead to severe pain and discomfort.	Baseline, Week 2, 6, 12, 26, 38, 52	No
Secondary	Change From Baseline in Number of Affected Body Parts by Enthesitis at Week 52	Enthesitis is the inflammation of the enthesis, where the joint capsules, ligaments or tendons attach to the bone. This inflammation can lead to severe pain and discomfort. In case of no presence of enthesitis the number of affected body parts was set to 0.	Baseline, Week 52	No
Secondary	Change From Baseline in C-Reactive Protein (CRP) at Week 52	The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.	Baseline, Week 52	No
Secondary	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Week 52	ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 millimeter/hour (mm/hr). A higher rate is consistent with inflammation.	Baseline, Week 52	No
Secondary	Percentage of Participants With Assessment in Ankylosing Spondylitis 20 (ASAS-20) Response	ASAS measures symptomatic improvement in AS participants. ASAS = 4 domains: participant global assessment of disease activity, pain, function, inflammation. ASAS 20= at least >= 20 percent improvement from baseline and an absolute change >=1 unit on a 0-10 numeric scale (0=no disease activity; 10=high disease activity) in at least 3 of the domains (on a 0-10 numerical scale): Global assessment of disease activity by participant, participant's global pain intensity, function measured by BASFI and inflammation measured by the average of the last two Likert-scales in BASDAI concerning morning stiffness intensity and duration and no worsening in the remaining domain.	Week 12, 26, 38, 52	No
Secondary	Percentage of Participants With Assessment in Ankylosing Spondylitis 40 (ASAS-40) Response	ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) participants. ASAS =4 domains: participant global assessment of disease activity, pain, function, inflammation. ASAS 40= at least (>=) 40 percent improvement from baseline and an absolute change >=2 unit on a 0-10 numeric scale (0=no disease activity; 10=high disease activity) in at least 3 of the domains (on a 0-10 numerical scale): Global assessment of disease activity by participant, participant's global pain intensity, function measured by BASFI and inflammation measured by the average of the last two Likert-scales in BASDAI concerning morning stiffness intensity and duration and no worsening in the remaining domain.	Week 12, 26, 38, 52	No
Secondary	Euro Quality of Life-5 Dimensions (EQ-5D) Time Trade Off (TTO)	EQ 5D: participant rated questionnaire to assess health-related quality of life. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (extreme problems). Score of each domain is transformed into a single TTO value using formula developed by Greiner et al and results in a total score range -0.205 to 0.999, higher score indicates a better health state.	Baseline, Week 26, 52	No
Secondary	Euro Quality of Life (EQ--5D)- Visual Analog Scale (VAS)	EQ-5D: participant rated questionnaire to assess health-related quality of life. Health. State Profile component assesses level of current health for 5 domains: mobility, self care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicate worst health state. Score of each domain is transformed into a single VAS score using formula developed by Greiner et al and results in a total score range of 0 to 100, where higher score indicates a better health state.	Baseline, Week 26, 52	No
Secondary	Work Productivity and Activity Impairment - Special Health Problems (WPAI:SHP)	WPAI:SHP is 6-question participant rated questionnaire to determine the amount of absenteeism, presenteeism, work productivity loss and daily activity impairment attributable to rheumatoid arthritis for a period of 7 days prior to each visit. It yields 4 sub-scores: work time missed (absenteeism), impairment while working (presenteeism or reduced on-the-job effectiveness), overall work impairment (work productivity loss or absenteeism plus presenteeism) and activity impairment (daily activity impairment). These sub-scores are transformed to impairment percentages (range from 0 to 100), with higher numbers indicating greater impairment and less productivity.	Baseline, Week 26, 52	No
Secondary	Healthcare Resource Utilization	Participants utilization of healthcare resources was evaluated as number of events for healthcare resources utilization including: number of visits to general practitioners, visits to rheumatologist, visits to other medical specialists, inpatient hospitalizations, inpatient rehabilitations, inpatient follow-up treatment, outpatient rehabilitations, physiotherapy, and other healthcare utilizations. At baseline, number of events for participants' healthcare resources utilization during last 12 months before enrollment into the study were documented. After enrollment, number of events for participants' healthcare resources utilization were documented for last 6 months after previous documentation.	Baseline, Week 26, 52	No
Secondary	Duration of Healthcare Resources Utilization	Participants duration of healthcare resources utilization was evaluated as number of days for healthcare resources utilization including: duration of visits to general practitioners, to rheumatologist, to other medical specialists, inpatient hospitalizations, inpatient rehabilitations, inpatient follow-up treatment, outpatient rehabilitations, physiotherapy, and other healthcare utilizations. At baseline, number of days for participants' healthcare resources utilizations during last 12 months before enrollment into the study were documented. After enrollment, number of days for participants' healthcare resources utilization were documented for last 6 months after previous documentation.	Baseline, Week 26, 52	No
Secondary	Percentage of Participants With Prior or Concomitant Medication Use for Treatment of Ankylosing Spondylitis	Participants taking any non-study medications which were administered either prior to or during the study treatment for AS were reported.	Baseline up to Week 52	Yes
Secondary	Percentage of Participants With Discontinuation of Treatment Due to Adverse Events	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.	Baseline up to Week 52	Yes

External Links

•   To obtain contact information for a study center near you, click here.